Just Like France Belgium disagrees with EMA and will veto against Finasteride Finasteride/Dutasteride 6/13/2025
Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Popular hair loss drug linked to higher suicide risk: compared to non-users, finasteride (Proscar/ Propecia) users have a markedly increased risk of depression, anxiety, and suicidal thoughts. Over 30 years of observation, 19,320 suicides were expected.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
community Publication concludes finasteride is a associated with a 60% risk of persistent sexual dysfunction.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
community Finasteride - impact on Neurosteroids, which yes, \are important and not a garbage hormone
Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.
community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.
Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.
Related Research
6 / 6 resultsresearch Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.
research Cosmeceutical Potentials of Equisetum debile Roxb. ex Vaucher Extracts
This study suggests that Equisetum debile extracts, particularly the ethyl acetate fraction, may offer natural cosmeceutical benefits for treating hyperpigmentation, delaying skin aging, and remediating hair loss due to androgenic alopecia.
research Farmácia Militar do Laboratório Nacional do Medicamento, Porto e Serviços Farmacêuticos do Centro Hospitalar Universitário do Porto (Hospital de Santo António), EPE, Porto
Pharmacists play a crucial role in patient care and optimizing treatment outcomes.
research Interventions for female pattern hair loss
This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.
research 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action
This study found that using a pharmacogenetic panel with 26 SNPs can improve treatment outcomes for androgenetic alopecia, as overall response rates to minoxidil, finasteride, and dutasteride were high, and specific genetic markers predicted poor responses to these drugs.